Angiopoietin-1 protects mesenchymal stem cells against serum deprivation and hypoxia-induced apoptosis through the PI3K/Akt pathway

Acta Pharmacologica Sinica

Volumn 29, Issue 7, 2008, Pages 815-822

  Liu, Xian Bao ^a   Jiang, Jun ^a   Gui, Chun ^a   Hu, Xin Yang ^b   Xiang, Mei Xiang ^b   Wang, Jian An ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

Angiopoiet in 1; Apoptosis; Mesenchymal stem cells; Tie 2 receptor

Indexed keywords

ANGIOPOIETIN 1; ANGIOPOIETIN RECEPTOR; ANGIOPOIETIN RECEPTOR FC FUSION PROTEIN; CASPASE 3; CASPASE 9; DIGOXIGENIN; DNA NUCLEOTIDYLEXOTRANSFERASE; HOE 33342; HYBRID PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B; RECOMBINANT HUMAN ANGIOPOIETIN 1; UNCLASSIFIED DRUG; WORTMANNIN; CASPASE; ONCOPROTEIN;

ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL CULTURE; CELL PROTECTION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; HYPOXIA; MESENCHYMAL STEM CELL; NICK END LABELING; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RAT; SERUM; SERUM DEPRIVATION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; ANIMAL; ANOXIA; CULTURE MEDIUM; DRUG EFFECT; HUMAN; PATHOLOGY; PHYSIOLOGY; SPRAGUE DAWLEY RAT; VASCULAR SMOOTH MUSCLE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANGIOPOIETIN-1; ANIMALS; ANOXIA; APOPTOSIS; CASPASES; CELL SURVIVAL; CULTURE MEDIA, SERUM-FREE; HUMANS; IN SITU NICK-END LABELING; MESENCHYMAL STEM CELLS; MUSCLE, SMOOTH, VASCULAR; ONCOGENE PROTEIN V-AKT; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION;

EID: 65849373134     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1111/j.1745-7254.2008.00811.x     Document Type: Article

References (36)

1. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999; 284: 143-7.
2. Orlic D, Kajstura J, Chimenti S, Jakoniuk I, Anderson SM, Li B, et al. Bone marrow cells regenerate infarcted myocardium. Nature 2001; 410: 701-5.
3. Wollert KC, Meyer GP, Lotz J, Ringes-Lichtenberg S, Lippolt P, Breidenbach C, et al. Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial. Lancet 2004; 364: 141-8.
4. Tomita S, Li RK, Weisel RD, Mickle DA, Kim EJ, Sakai T, et al. Autologous transplantation of bone marrow cells improves damaged heart function. Circulation 1999; 100: II247-56.
5. Hu X, Wang J, Chen J, Luo R, He A, Xie X, et al. Optimal temporal delivery of bone mar row mesenchymal stem cells in rats with myocardial infarction. Eur J Cardiothorac Surg 2007; 31: 438-43.
6. Wang JA, Fan YQ, Li CL, He H, Sun Y, Lv BJ. Human bone marrow-derived mesenchymal stem cells transplanted into damaged rabbit heart to improve heart function. J Zhejiang Univ Sci B 2005; 6: 242-8.
7. Wang JA, Li CL, Fan YQ, He H, Sun Y. Allograftic bone marrowderived mesenchymal stem cells transplanted into heart infarcted model of rabbit to renovate infarcted heart. J Zhejiang Univ Sci 2004; 5: 1279-85.
8. Kolossov E, Bostani T, Roell W, Breitbach M, Pillekamp F, Nygren JM, et al. Engraftment of engineered ES cell-derived cardiomyocytes but not BM cells restores contractile function to the infarcted myocardium. J Exp Med 2006; 203: 2315-27.
9. Lunde K, Solheim S, Aakhus S, Arnesen H, Abdelnoor M, Egeland T, et al. Intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction. N Engl J Med 2006; 355: 1199-209.
10. Toma C, Pittenger MF, Cahill KS, Byrne BJ, Kessler PD. Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart. Circulation 2002; 105: 93-8.
11. Zhang M, Methot D, Poppa V, Fujio Y, Walsh K, Murry CE. Cardiomyocyte grafting for cardiac repair: graft cell death and anti-death strategies. J Mol Cell Cardiol 2001; 33: 907-21.
12. Davis S, Aldrich TH, Jones PF, Acheson A, Compton DL, Jain V, et al. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell 1996; 87: 1161-9.
13. Dumont DJ, Yamaguchi TP, Conlon RA, Rossant J, Breitman ML. Tek, a novel tyrosine kinase gene located on mouse chromosome 4, is expressed in endothelial cells and their presumptive precursors. Oncogene 1992; 7: 1471-80.
14. Maisonpierre PC, Goldfarb M, Yancopoulos GD, Gao G. Distinct rat genes with related profiles of expression define a TIE receptor tyrosine kinase family. Oncogene 1993; 8: 1631-7.
15. Thurston G. Role of angiopoietins and Tie receptor tyrosine kinases in angiogenesis and lymphangiogenesis. Cell Tissue Res 2003; 314: 61-8.
16. Papapetropoulos A, Garcia-Cardena G, Dengler TJ, Maisonpierre PC, Yancopoulos GD, Sessa WC. Direct actions of angiopoietin- 1 on human endothel ium: evidence for network stabilizat ion, cell survival, and interaction with other angiogenic growth factors. Lab Invest 1999; 79: 213-23.
17. Kwak HJ, So JN, Lee SJ, Kim I, Koh GY. Angiopoietin-1 is an apoptosis survival factor for endothelial cells. FEBS Lett 1999; 448: 249-53.
18. Valable S, Bellail A, Lesne S, Liot G, Mackenzie ET, Vivien D, et al. Angiopoietin-1-induced PI3-kinase activation prevents neuronal apoptosis. FASEB J 2003; 17: 443-5.
19. Hashiramoto A, Sakai C, Yoshida K, Tsumiyama K, Miura Y, Shiozawa K, et al. Angiopoietin 1 directly induces destruction of the rheumatoid joint by cooperative, but independent, signaling via ERK/MAPK and phosphatidylinositol 3-kinase/Akt. Arthritis Rheum 2007; 56: 2170-9.
20. Wang Z, Cui M, Sun L, Jia Z, Bai Y, Ma K, et al. Angiopoietin- 1 protects H9c2 cells from H2O2-induced apoptosis through AKT signaling. Biochem Biophys Res Commun 2007; 359: 685-90.
21. Xie XJ, Wang JA, Cao J, Zhang X. Differentiation of bone marrow mesenchymal stem cells induced by myocardial medium under hypoxic conditions. Acta Pharmacol Sin 2006; 27: 1153- 8.
22. Zhu W, Chen J, Cong X, Hu S, Chen X. Hypoxia and serum deprivation-induced apoptosis in mesenchymal stem cells. Stem Cells 2006; 24: 416-25.
23. Perin EC, Geng YJ, Willerson JT. Adult stem cell therapy in perspective. Circulation 2003; 107: 935-8.
24. Tang YL, Tang Y, Zhang YC, Qian K, Shen L, Phi ll ips MI. Improved graft mesenchymal stem cell survival in ischemic heart with a hypoxia-regulated heme oxygenase-1 vector. J Am Coll Cardiol 2005; 46: 1339-50.
25. Jiang S, Haider H, Idris NM, Salim A, Ashraf M. Supportive interaction between cell survival signaling and angiocompetent factors enhances donor cell survival and promotes angiomyogenesis for cardiac repair. Circ Res 2006; 99: 776-84.
26. Mangi AA, Noiseux N, Kong D, He H, Rezvani M, Ingwall JS, et al. Mesenchymal stem cells modified with Akt prevent remodeling and restore performance of infarcted hearts. Nat Med 2003; 9: 1195-201.
27. Kaiser J. Clinical research. Death prompts a review of gene therapy vector. Science 2007; 317: 580.
28. Kaiser J. Gene therapy. Side effects sideline hemophilia trial. Science 2004; 304: 1423-5.
29. Kim I, Kim HG, So JN, Kim JH, Kwak HJ, Koh GY. Angiopoietin- 1 regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Circ Res 2000; 86: 24-9.
30. Fayard E, Tintignac LA, Baudry A, Hemmings BA. Protein kinase B/Akt at a glance. J Cell Sci 2005; 118: 5675-8.
31. Ashkenazi A, Dixi t VM. Death receptors: signa l ing and modulation. Science 1998; 281: 1305-8.
32. Green DR, Reed JC. Mitochondria and apoptosis. Science 1998; 281: 1309-12.
33. Gross A, Jockel J, Wei MC, Korsmeyer SJ. Enforced dimerization of BAX results in its translocation, mitochondrial dysfunction and apoptosis. EMBO J 1998; 17: 3878-85.
34. Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993; 74: 609-19.
35. Yang E, Korsmeyer SJ. Molecular thanatopsis: a discourse on the BCL2 family and cell death. Blood 1996; 88: 386-401.
36. Lakhani SA, Masud A, Kuida K, Porter GA Jr, Booth CJ, Mehal WZ, et al. Caspases 3 and 7: key mediators of mitochondrial events of apoptosis. Science 2006; 311: 847-51.